Skip to main content

Table 2 General characteristics of 312 discontinued drug clinical trials in China

From: General characteristics and reasons for the discontinuation of drug clinical trials in mainland China

Characteristic

% (n)

Research institute

 Tertiary hospital

91.3 (285)

 Secondary hospital

1.6 (5)

 Scientific research institution

1.3 (4)

 Others

5.8 (18)

Study design

 Parallel assignment

54.2 (169)

 Crossover assignment

34.9 (109)

 Single group assignment

10.9 (34)

Randomization status

 Randomized

90.4 (282)

 Non-randomized

9.6 (30)

Blinding status

 Open label

57.1 (178)

 Single blind

4.2 (13)

 Double blind

38.8 (121)

No. of centers

 Single center trial

45.5 (142)

 Multiple center trial

54.5 (170)

Control type

 Active drug

49.4 (154)

 Placebo control

33.7 (105)

 Blank control

0.6 (2)

 Uncontrolled

16.3 (51)

Sample size

  < 100 participants

50.0 (156)

 100–499 participants

34.0 (106)

  > 500 participants

11.9 (37)

 Unclear

4.2 (13)

Has enrolled participants

 Yes

43.3 (135)

 No

56.7 (177)

DMC has been established

 Yes

17.0 (53)

 No

83.0 (259)

Insurance has been purchased

 Yes

48.4 (151)

 No

51.6 (161)

  1. Abbreviation: DMC data monitoring committee